Pentamidine

Chris hiley, head of policy and research, brings you a selection of the latest research looking at the treatments and genetic causes of prostate cancer.

The only data on the whole animal loss of TMAO in elasmobranchs are the study of Goldstein and Palatt 10 ; , in which a loss coefficient for radiolabeled TMAO-- equivalent to the proportion of whole animal TMAO lost per day--was determined in four species. This often-cited study for example, see recent reviews 20, 29 ; found that the loss coefficient for TMAO ranged from 4 to 14% per day depending on the species 10 ; . Whole animal TMAO efflux rates of this magnitude would make it impossible to maintain levels of TMAO for prolonged periods without feeding in elasmobranch species that lack endogenous synthesis. For example, the loss coefficients were calculated to be 10.4 and 7.8% per day for S. acanthias and L. erinacea, respectively; or a loss of 50 and 40% of the total body TMAO pool, respectively, after 1 wk of food deprivation. There is no evidence for such precipitous declines in TMAO content for either species. Thus either 1 ; the data indicating a lack of synthesis are erroneous, 2 ; the determined rate of TMAO loss in elasmobranchs is an overestimate, or 3 ; both of these aspects of TMAO metabolism are in need of reassessment. The present study was undertaken to determine which of the above cases is correct. For this, we use the winter skate L. ocellata ; , a species that we have recently reported also lacks detectable oxygenation of TMA in the liver 25 ; , using the methodology criticized by Schlenk 18 ; . A series of experiments were designed to determine whether winter skates could maintain circulating TMAO concentrations without feeding and subsequently to elucidate whether this was due to endogenous synthesis, low excretion rates, or a combination thereof. By the nature of these experiments, a number of other aspects of TMAO accumulation were also assessed, including the contribution of TMAO plus TMA ; to whole animal nitrogen excretion, the relationship between extracellular TMAO concentration, and the accumulation of intracellular TMAO which is indicative of an active uptake mechanism ; and the relative permeability of several tissues to TMAO!

IR content: normal vs. cancer total ; , P 0.0011. IR-A relative abundance: normal vs. cancer total ; , P 0.0042 by Mann-Whitney test and pentasa.
More than 10, 000 cases of Pneumocystis carinii pneumonia have been reported in the United States to the Centers for Disease Control since the emergence of the acquired immunodeficiency syndrome epidemic 5 ; . P. carinii infection is confined to the lungs. Trimethoprim-sulfamethoxazole TMP-SMZ ; and pentamidine are the two drugs which are routinely used in treating human P. carinii pneumonia. However, the parenteral administration of pentamidine is hampered by frequent local intolerance and major systemic side effects due to its high level of extrapulmonary deposition. TMP-SMZ side effects are also frequent, especially in acquired immunodeficiency syndrome patients. Since preliminary data on aerosolized pentamidine pharmacokinetics were available E. M. Bernard, H. P. Donelly, H. P. Koo, and D. Amstrong, Program Abstr. 25th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 552, 1985 ; , we tested the feasibility, tolerance, and efficacy of pentamidine aerosol in the prophylaxis and therapeutic treatment of murine P. carinii pneumonia. MATERIALS AND METHODS Animal model of P. carinii pneumonia. Male SpragueDawley rats Charles River Breeding Laboratories, St. Aubin, France ; , weighing 200 to 250 g, were housed in groups of five in conventional cages with standard rat chow no. A03; Usine Alimentation Rationelle, Villemoisson, France ; and water ad libitum. Rats were weighed weekly. Rats were immunosuppressed by subcutaneous injections of 25 mg of cortisone acetate Hydrocortisone; HoechstRoussel, Paris, France ; twice weekly, until death or sacrifice. Doxycycline Vibramycine; Pfizer Inc., Paris, France ; was subcutaneously injected at a dose of 10 mg twice weekly to prevent bacterial superinfection. This model has been.

All natural hydrating crystals may be used as an aroma therapeutic bath treatment or as an exfoliating scrub. Just pour a small amount into warm water or a whirlpool to create a special skin softening experience. To use as an exfoliate, just shake a small amount in your hand along with our Peach Conditioning Cuticle Oil to make a paste. This fragrant paste can then be used as in invigorating spa scrub and exfoliate to revitalize your skin!

Autologous bone marrow support in the Duke University Bone Marrow Transplant Program is approximately 39 to 69%.6, 7, 21 Most patients in whom infection is ruled out have a low mortality rate and a prompt response to prednisone therapy. Because of these features, we have termed this posttransplant complication DPTS.6 DPTS is to be contrasted to IPS, a syndrome characterized by severe hypoxemia, radiographic infiltrates, and high mortality.4 Our patient demonstrated three phases of pulmonary toxic reactions. Phase I is subclinical and asymptomatic and is best characterized by a decreased Dlco measurement following the first three cycles of the CAF induction chemotherapy Fig 1 ; . Little is known about the contribution that the conditioning regimen plays in the development of lung injury. Phase II occurred following HDC ABMT and was diagnosed as DPTS based on its timing, associated pulmonary symptoms, decrease in Dlco, and prompt response to corticosteroid therapy with subsequent improvement in Dlco. Phase III occurred approximately 158 days following BMT when the patient developed acute respiratory failure. Was coronavirus pneumonia responsible for her respiratory failure? We believe so. The BAL sample was obtained 36 h after intubation and the bronchoscope was placed into the lumen of the endotracheal tube, thus minimizing possible nasal mucosa contamination. We have considered other possibilities. For example, the coronavirus could simply have been present in the BAL specimen, but was not pathogenic. In this scenario, the etiology of the respiratory failure could have been caused by several different factors, including radiation pneumonitis, druginduced interstitial pneumonitis, or showering of the lung with inflammatory cytokines from an abdominal or septic source resulting in ARDS. Radiation pneumonitis seems less likely since the pattern of radiographic lung injury does not duplicate the radiation port, 6 although case studies have shown that radiation pneumonitis can occur. Chlorpromazine is preferably administered at a dosage of 10 to 2500 milligrams and pentamidine is preferably administered at a dosage of 1 to 1000 milligrams and percodan.

14 Robinson DS, Cunningham DA, Dave S, Fleming J, Mitchell DM. Diagnostic value of lung clearance of 99mTc DTPA compared with other non-invasive investigations in Pneumocystis carinii pneumonia in AIDS. Thorax 1991; 46: 722726. Monaghan P, Provan I, Murray C, et al. An improved radionuclide technique for the detection of altered pulmonary permeability. J Nucl Med 1991; 32: 19451949. Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIVinfected persons. Pulmonary Complications of HIV Infection Study Group. J Respir Crit Care Med 1997; 155: 6066. Huang L, Stansell J, Osmond D, et al. Performance of an algorithm to detect Pneumocystis carinii pneumonia in symptomatic HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Chest 1999; 115: 10251032. Boldt MJ, Bai TR. Utility of lactate dehydrogenase vs radiographic severity in the differential diagnosis of Pneumocystis carinii pneumonia. Chest 1997; 111: 11871192. Huang L, Hecht FM, Stansell JD, Montanti R, Hadley WK, Hopewell PC. Suspected Pneumocystis carinii pneumonia with a negative induced sputum examination. Is early bronchoscopy useful? J Respir Crit Care Med 1995; 151: 18661871. Wharton JM, Coleman DL, Wofsy CB, et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med 1986; 105: 3744. The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323: 15001504. Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1990; 323: 14511457. Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey OW, La Voie L. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebocontrolled trial. N Engl J Med 1990; 323: 14441450. Montaner JS, Lawson LM, Levitt N, Belzberg A, Schechter MT, Ruedy J. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome AIDS ; . Ann Intern Med 1990; 113: 1420. Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprimsulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 1996; 124: 792802. The Five Minute Speech Sample for the Parent-Physician Relationship Magana-Amato, 1989 ; . The FMSS was used to assess criticism and emotional overinvolvement in the client-therapist relationship in a manner fashioned after that employed by Stark and Soil 1984 ; . The physician was asked to speak for five uninterrupted minutes, offering thoughts and feelings about the parent, what it was like working with the parent, and how he or she got along with this parent. Physicians were given the following probe: "I'd like to hear your thoughts and feelings about Mrs. Brown in your own words without my interrupting with any questions or comments. When I ask you to begin I'd like you to tell me what kind of person Mrs. Brown is and what it was like working with her during this hospitalization. After you begin to speak, I prefer not to ask any questions until the five minutes are over. Do you have any questions before we begin?" Once the physician began to speak, minimal probes were then provided, other than "Please tell me anything about Mrs. Brown for just a few more minutes." The parents were also asked to speak for five uninterrupted minutes, stating their thoughts and feelings about the physician, what kind of physician he or she is, and how the physician got along with their family. Parents received the following probe: "I'd like to hear your thoughts and feelings and pergolide. Idine at one-half of its MIC could not be evaluated in this in vivo system due to inhibitory effects on test strain growth. The transcription of mepA in SA-K2982 was low compared to that of mepR in SA-K2916. Under these circumstances, mepR expression was approximately a thousand times that of mepA. These data are consistent with previous Northern blot analyses of S. aureus NCTC 8325-4 revealing the presence of mepR but no mepA or mepB transcripts 10 ; . In contrast to the effect of substrate exposure on mepR expression just presented, exposure of SA-K2982 to one-quarter of the respective MIC of BAC, dequalinium, EtBr, or pentamidine resulted in substantially increased mepA transcription Table 3 ; . Regulatory proteins for other MDR efflux pumps that have been studied, including BmrR of Bacillus subtilis and QacR of S. aureus, have been shown to have their activity altered by the binding of substrate to them 7, 22, 24 ; . In fact, MarR also is a ligandbinding protein salicylate ; , and such binding results in abro.
We report herein, the predominant cell type in idiopathic granulomatous vasculitis of the central nervous system has been the CD4 T lymphocyte. The inflammatory infiltrate in our patient was predominantly lymphocytic, and most cells were CD4- CD8- CD3 + T cells. This antigenic configuration is probably consistent with immature T lymphocytes, since natural killer cells do not express CD3 molecules. This case of inflammatory and partly destructive myelopathy was predicated on a leptomeningeal vasculitis. Fibrinoid occlusion of many vessels was a peculiar feature. A condition such as this should be considered when there is a persistent meningeal inflammatory reaction, corticosteroid-related improvement in clinical features, and a normal magnetic resonance imaging scan. Accepted for publication June 27, 2003. Author contributions: Study concept and design Drs Ropper and Adelman acquisition of data Drs Ropper, Ayata, and Adelman analysis and interpretation of data Drs Ropper, Ayata, and Adelman drafting of the manuscript Drs Ropper, Ayata, and Adelman critical revision of the manuscript for important intellectual content Dr Adelman ; . Corresponding author and reprints: Allan H.Ropper, MD, Division of Neurology, St Elizabeth's Medical Center, 736 Cambridge St, Boston, MA 02135 e-mail: aropperm cchcs and permax.

FIG. 3. Facial appearance of three subjects receiving long-term therapy with rhIGF-I. Second subject female ; shows coarsening of facial features with overgrowth of soft tissues of nose and lips during therapy. Changes in first subject are less apparent. After week 3, your doctor may decide that your dosage should be increased. If so, he or she will provide further instruction on how to take your medication. Remember, do not increase your dosage unless instructed by your doctor and phenazopyridine and pentamidine.
Because many processes can present with similar clinical manifestations, a specific diagnosis of PCP should be sought rather than relying on a presumptive diagnosis. Treatment can be initiated prior to making a definitive diagnosis since organisms persist in clinical specimens for days or weeks after effective therapy is initiated. Treatment Recommendations Trimethoprim-sulfamethoxazole TMP-SMX ; is the treatment of first choice see Appendix B ; . The dose must be adjusted for abnormal renal function. Adding leucovorin to prevent myelosuppression during acute treatment is not recommended due to questionable efficacy and some evidence of a higher failure rate. Oral outpatient therapy of TMP-SMX is highly effective in patients with mild to moderate disease. Patients who develop PCP despite TMPSMX prophylaxis are usually effectively treated with standard doses of TMP-SMX. Patients with documented PCP and moderate to severe disease as defined by pO2 of 70mmHg or [A-a]DO2 of 35mmHg should receive corticosteroids as early as possible and certainly within seventy-two hours after starting specific PCP therapy. If steroids are started at a later time, it is not clear that they provide any benefit, although most clinicians would use them in such circumstances for patients with severe disease. The preferred corticosteroid dose and regimen is prednisone 40mg by mouth twice daily for days one through five, 40mg daily for days six through ten, and 20mg daily for days eleven through twenty-one. Methylprednisolone at 75% of the respective prednisone dose can be used if parenteral administration is necessary. Alternative therapeutic regimens include: a ; dapsone plus TMP for mild to moderate disease this regimen may have similar efficacy and fewer side effects than TMP-SMX but is less convenient because of the number of pills b ; primaquine plus clindamycin this regimen is also effective in mild to moderate disease, and the clindamycin component can be administered intravenously for more severe cases; however, primaquine is only available orally c ; intravenous IV ; pentamidine generally the drug of second choice for severe disease d ; atovaquone suspension this is less effective than TMP-SMX for mild to moderate disease but has fewer side effects and e ; trimetrexate with leucovorin this is less effective than TMP-SMX but may be used if the latter is not tolerated and an IV regimen is needed ; , although leucovorin must be continued three days after the last trimetrexate dose. The addition of dapsone, SMX, or sulfadiazine to trimetrexate may improve efficacy based on the sequential enzyme blockade of folate metabolism, although there are no study data available to confirm this. Aerosolised pentamidine should not be used for the treatment of PCP because of limited efficacy and more frequent relapse. The recommended duration of therapy for PCP is twenty-one days. Overall, the probability and rate of response to therapy depends on the agent used, number of prior episodes, severity of illness, degree of immunodeficiency, and timing of initiation of therapy. Although the overall prognosis of patients whose degree of hypoxaemia requires ICU admission or whose mechanical ventilation remains poor, survival in up to 40% of patients requiring ventilatory support has been reported in recent years. Because long-term survival is possible for those patients for whom HAART is effective, many patients with AIDS and severe PCP should be offered ICU admission or mechanical ventilation when appropriate, e.g. when they have good functional status and no concurrent life-threatening processes. Because of the potential for additive or synergistic toxicities associated with anti-PCP and HAART, many experts delay initiation of HAART until after the completion of anti-PCP therapy despite some suggestion of potential benefit for early HAART. An inflammatory IRS has been described for PCP and may complicate the concurrent administration of anti-PCP treatment and HAART. Monitoring and Adverse Events.
The migrant workers labour as domestic help, sales assistants, construction workers, weavers, sewers, seafood sorters, fisher people, farm labourers, petrol pump attendants, rubbish collectors, abattoir workers, salt miners, plantation labourers, factory and sex workers Awataya Panam, Khaing Mar Kyaw Zaw, Caouette, & Sureeporn Punpuing, 2004; Human Rights Documentation Unit & Burmese Women's Union, 2000; Images Asia, 1997; Pim Koetsawang, 2001; Sunday Perspective Reporters, 2001 ; .26 Table 6 shows the type of work available to Burmese workers and their average wages and phenelzine.

MEGLUMINE ANTIMONATE: in WHO Model List of Essential Drugs Indications: leishmaniasis 92% cure rate in cutaneous, 66% in visceral ; , schistosomiasis Side Effects: chemical pancreatitis in 30%, cardiotoxicity in 14% PENTAMIDINE ISETHIONATE: in WHO Model List of Essential Drugs as main list drug to improve compliance Indications: babesiosis; leishmaniasis 95% cure rate in cutaneous treatment and prophylaxis of haemolymphatic trypanosomiasis due to Tyrpanosoma brucei gambiense Side Effects: i.v.: immediate hypotension, nausea and vomiting; later, local pain at injection site, abscess formation, neutropenia frequent in AIDS ; , thrombocytopenia, rash rare ; , nephrotoxicity mild azotemia to severe tubular necrosis ; , hepatitis with abnormal liver function tests, hypoglycaemia and hyperglycaemia, cardiotoxicity in 23% of patients treated for antimony-resistant kala azar, hypomagnesia, hypokalemia, acute pancreatitis, ventricular arrhythmias; severe hypocalcaemia with foscarnet; possible potentiation of toxic effects on rapidly growing cells bone marrow, spermatogonia, germinal layers of skin and gastrointestinal mucosa ; with ganciclovir; possible potentiation of nephrotoxicity including acute renal failure ; with amphotericin, cidofovir, foscarnet, other nephrotoxic agents; diabetes in 20% of patients treated for 3 weeks; increased risk of QT prolongation with all drugs capable of prolonging QT interval; dose adjustment required in renal failure, not in dialysis except continuous venovenous or arteriovenous haemodialysis aerosolised: bronchospasm, acute pancreatitis, mild hypoglycaemia, increased risk of spontaneous pneumothorax; safety in pregnancy not established Contraindications: avoid in breastfeeding insufficietn data ; ALLOPURINOL Indications: isolated skin lesions due to Leishmania braziliensis, Leishmania mexicana; visceral leishmaniasis Side Effects: skin rash, mild fever, dyspepsia, nausea, vomiting, colic, diarrhoea, drowsiness, headache, peripheral neuritis, liver enlargement KETOCONAZOLE Indications: isolated skin lesions due to Leishmania braziliensis, Leishmania mexicana Side Effects: see Chapter 22 INTERLEUKIN 2 Indications: isolated skin lesions due to Leishmania braziliensis, Leishmania mexicana METHYLBENZETHONIUM Indications: localised skin lesions due to Leishmania tropica GAMMA INTERFERON Indications: visceral leishmaniasis MILTEFOSINE: oral Indications: visceral leishmaniasis PYRIMETHAMINE-SULPHADIAZINE Indications: Toxoplasma brain and epidural abscess, encephalitis 80-90% effective ; , meningitis, retinochoroditis, infections in pregnancy Side Effects: seen in 30-45% of patients; severe skin rash, leucopoenia, thrombocytopenia, elevated levels of serum transaminases, bone marrow toxicity, pancytopenia, megaloblastic anaemia SULPHONAMIDES Indications: cerebral toxoplasmosis in AIDS Side Effects: see Chapter 21 AZITHROMYCIN: macrolide Indications: treatment of cerebral toxoplasmosis in AIDS Side Effects: see Chapter 21 COTRIMOXAZOLE Indications: enteritis due to Isospora belli; Toxoplasma gondii; toxoplasmosis including anterior uveitis, brain and epidural abscess, hydrocephalus, hepatitis and hepatic granuloma, pancreatitis, prophylaxis in AIDS in WHO Model List of Essential Drugs Side Effects: see Chapter 21 SPIRAMYCIN: macrolide Indications: enteritis due to Cryptosporidium; toxoplasmosis including meningitis, pancreatitis ; Side Effects: see Chapter 21 ERYTHROMYCIN: macrolide Indications: enteritis due to Cryptosporidium Side Effects: see Chapter 21 ROXITHROMYCIN: macrolide Indications: enteritis due to Isospora belli Side Effects: see Chapter 21. However, when necessary, the use of intravenous pentamidine has an acceptably low failure rate, even in high-risk bmt patients. 65. Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, Herold M, Krebs B, Veit O, Allwinn R, Steffen R, 2003. Tolerability of malaria chemoprophylaxis in non-immune travelers to sub-Saharan Africa: Multicenter, randomized, double-blind, four arm study. BMJ 329: 1078 1081. Simons R, Valk P, Krul AJ, 2005. Malaria prophylaxis for aircrew: Safety of atovaquone proguanil in health volunteers under aircraft cabin pressure conditions. J Travel Med 12: 210 216. Emberger M, Lechner AM, Zelger B, 2003. Stevens-Johnson syndrome associated with malarone antimalarial prophylaxis. Clin Infect Dis 37: e5e7. 68. Grieshaber M, Lammli J, Marcus L, 2005. Acute hepatitis and atovaquone proguanil. J Trav Med 12: 289290. 69. Sabchareon A, Attanath P, Phanuaksook P, Chanthavanich P, Poonpanich Y, Mookmanee D, Chongsuphajaisiddhi T, Sadler BM, Hussein Z, Canfield CJ, Hutchinson D, 1998. Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug resistant Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 92: 201206. 70. Thybo S, Gjorup I, Ronn A, Meyrowitsch D, Bygberg IC, 2004. Atovaquone-proguanil Malarone ; : An effective treatment for uncomplicated Plasmodium falciparum malaria in travelers from Denmark. J Travel Med 11: 220224. 71. Lobel HO, Miani M, Eng T, Bernard KW, Hightower AW, Campbell CC, 1993. Long-term malaria prophylaxis with weekly mefloquine. Lancet 341: 848851. 72. Gozal D, Hengy C, Fadat G, 1991. Prolonged malaria prophylaxis with chloroquine and proguanil chloroguanide ; in a nonimmune resident population of an endemic area with a high prevalence of chloroquine resistance. Antimicrob Agents Chemother 35: 373376. 73. Saraux A, Taelman H, Van der Stuyft P, Dabis F, 1992. Effectiveness of long-term malaria chemoprophylaxis among French expatriates residing in Rwanda. Ann Soc Belg Med Trop 72: 225227. 74. GlaxoSmithKline Inc, 1999. Mepron Brand of Atovaquone Suspension. GSK Product Monograph. Research Triangle Park, NC: GSK. 75. El-Sadr WM, Murphy RL, Yurik TM, Luskin-Hawk R, Cheung TW, Balfour HH Jr, Eng R, Hooton TM, Kerkering TM, Schutz M, van der Horst C, Hafner R, 1998. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J Med 339: 18891895. 76. Hughes WT, Dankar WM, Yogev R, Huang S, Paul ME, Flores MA, Kline MW, Wei LJ, 2005. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. Clin Infect Dis 40: 136145. 77. Chan C, Montaner J, Lefebvre EA, Morey G, Dohn M, McIvor RA, Scott J, Marina R, Caldwell P, 1999. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 180: 369376. Ambulatory Blood Pressure Monitoring ABPM ; . 24 Consolidated Billing for Skilled Nursing Facility SNF ; Residents . 27 Radiation Therapy R-4 ; . 24 The Use of Gamma Cameras and Full-Ring and PartialRing Positron Emission Tomography PET ; Scans . 24.
Tachycardia, ventricular effects on carotid artery blood flow velocity, 60 Tachypnea respiratory pattern disturbances in ischemic cerebral vascular disease, 612 Takayasu's disease platelet alterations in, 294 Technetium-99m effects of dexamethasone, 617 Telangiectasia cerebrovascular malformations in hereditary hemorrhagir. 267 Thalamus anatomo-clinical study of thalamic hemorrhage, 102 and pentasa. The Official Publication of the CMSC, RIMS and IOMSN Increasingly, studies in MS, regardless of hypothesis es ; to be tested, involve collaborative research including many centres. There are many advantages to such collaborations as well as many potential pitfalls. The Canadian Collaborative Project on Genetic Susceptibility to MS CCPGSMS ; formally began in 1993 when funding was first received. As far as we are aware, Canada is the only example of a country where all specialized clinics work together on a single collaborative project. This collaboration overrides boundaries of geography, language, and culture. Subjects include over 20, 000 MS patients, their family members, and spouses. All 13 official Canadian MS Clinics are involved in this study. It is therefore critical that all data are uniformly and accurately collected and verified by study personnel at each participating clinic. Over the years, we have learned much about the advantages and disadvantages of multicentre collaborative efforts as well as the "dos" and "don'ts" in coordinating such an endeavor over a large geographic region. Issues to be discussed based on the Canadian experience include: autonomy versus supervision, communication, adapting questionnaires yet maintaining consistency, allocation of responsibilities eg, grant submission, paper submission, etc. ; , allocation of funds, assessment of productivity, discipline eg, with respect to confidentiality ; , what each collaborator sees as "benefits, " and what each collaborator sees as "costs. 15: 575-578. 19. Kim, C. K., J. M. Foy, M. T. Cushion, D. Stanforth, M. J. Linke, H. L. Hendrix, and P. D. Walzer. 1987. Comparison of histologic and quantitative techniques in evaluation of therapy for experimental Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 31: 197-201. 20. Kirby, H. B., B. Kenamore, and J. C. Guckian. 1971. Pneumocystis carinii pneumonia treated with pyrimethamine and sulfadiazine. Ann. Intern. Med. 75: 505-509. 21. Kluge, R. M., D. M. Spaulding, and A. J. Spain. 1978. Combination of pentamidine and trimethoprim-sulfamethoxazole in the therapy of Pneumocystis carinii pneumonia in rats. Antimicrob. Agents Chemother. 13: 975-978. 22. Kovacs, J. A., C. J. Allegra, B. A. Chabner, J. C. Swan, J. Drake, M. Lunde, J. E. Parrillo, and H. Masur. 1987. Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii. J. Infect. Dis. 155: 1027-1032. 23. Kovacs, J. A., J. W. Hiemenz, A. M. Macher, D. Stover, H. W. Murray, J. Shelhamer, H. C. Lane, C. Urmacher, C. Honig, D. L. Longo, M. M. Parker, C. Natanson, J. E. Parrillo, A. S. Fauci, P. A. Pizzo, and H. Masur. 1984. Pneumocystis carinii pneumonia: a comparison between patients with the acquired 24. Points, paths, pens, and pictures can be shifted, scaled, rotated, and revamped in a variety of ways. Our aim in this chapter will be to learn all about the builtin metamorphoses of , because they can make programs simpler and more versatile. The basic transformations have already appeared in many examples, but let's start by reviewing them here: x, y ; x, y ; x, y ; x, shifted a, b ; scaled s xscaled s yscaled s slanted s rotated zscaled u, v ; x + a, sx, sy sx, y x, sy x + sy, y x cos - y sin , x sin + y cos xu - yv, xv + yu.